SRPT Sarepta Therapeutics Inc.

116.64
-2.09  -2%
Previous Close 118.73
Open 119.01
Price To Book 8.05
Market Cap 8315513927
Shares 71,292,129
Volume 2,391,551
Short Ratio
Av. Daily Volume 1,435,223

NewsSee all news

  1. Wave Life Sciences Plunges After DMD Study Data Readout
  2. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  3. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  4. 4 Gene Therapy Players Likely to Become Buyout Targets in 2019
  5. Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released March 28, 2019. Mid-2019 NDA filing expected.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 updated data released October 3, 2018.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Phase 1 trial safety and dosing insight due by end of 2019.
SRP-5051 - PPMO
Duchenne muscular dystrophy
PDUFA date under priority review August 19, 2019 .
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 data February 27, 2019 noted mean of 51% beta-sarcoglycan positive fibers.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)

Latest News

  1. Wave Life Sciences Plunges After DMD Study Data Readout
  2. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  3. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  4. 4 Gene Therapy Players Likely to Become Buyout Targets in 2019
  5. Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
  6. Ex-Sarepta execs join new Atlas-backed muscular disease startup fueled by $50M
  7. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  8. How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key Market
  9. Sarepta plans second Duchenne drug application this year
  10. Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug
  11. Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
  12. 8 Genomic Testing Stocks That Can Ease the Sting of Theranos
  13. Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now?
  14. Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
  15. Sarepta Therapeutics' Charts Look Risky
  16. Sarepta or Amarin: Who Is Controlling Expenses Better?
  17. Sarepta and Amarin: What to Expect from Their EPS Growth
  18. Sarepta or Amarin: Who’s Expected to Post Faster Revenue Growth?
  19. What Analysts Recommend for Sarepta and Amarin in March